Brinker Capital Investments LLC Sells 21,142 Shares of Pfizer Inc. (NYSE:PFE)

Brinker Capital Investments LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.9% during the first quarter, HoldingsChannel.com reports. The firm owned 245,108 shares of the biopharmaceutical company’s stock after selling 21,142 shares during the quarter. Brinker Capital Investments LLC’s holdings in Pfizer were worth $8,881,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in PFE. Norges Bank bought a new stake in shares of Pfizer during the 4th quarter valued at $2,219,532,000. BlackRock Inc. increased its stake in Pfizer by 2.2% in the 1st quarter. BlackRock Inc. now owns 405,733,970 shares of the biopharmaceutical company’s stock worth $14,699,742,000 after acquiring an additional 8,760,458 shares during the last quarter. Morgan Stanley increased its stake in Pfizer by 16.4% in the 4th quarter. Morgan Stanley now owns 53,610,111 shares of the biopharmaceutical company’s stock worth $1,973,389,000 after acquiring an additional 7,540,245 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Pfizer by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 64,756,839 shares of the biopharmaceutical company’s stock worth $2,383,700,000 after acquiring an additional 6,965,496 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in Pfizer in the 4th quarter worth about $162,707,000. Institutional investors own 64.22% of the company’s stock.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the transaction, the senior vice president now owns 13,748 shares in the company, valued at approximately $561,193.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.

PFE opened at $40.68 on Friday. The stock has a market cap of $227.71 billion, a PE ratio of 20.76, a PEG ratio of 1.42 and a beta of 0.74. The company has a current ratio of 1.48, a quick ratio of 1.16 and a debt-to-equity ratio of 0.51. The company has a 50 day moving average price of $38.76. Pfizer Inc. has a 52 week low of $31.61 and a 52 week high of $43.08.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 4th. The biopharmaceutical company reported $0.93 EPS for the quarter, beating the Zacks’ consensus estimate of $0.78 by $0.15. The company had revenue of $14.58 billion during the quarter, compared to analysts’ expectations of $13.41 billion. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. The firm’s revenue for the quarter was up 44.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.80 EPS. Sell-side analysts predict that Pfizer Inc. will post 3.69 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.83%. The ex-dividend date of this dividend was Thursday, May 6th. Pfizer’s payout ratio is presently 70.27%.

Several equities analysts have recently commented on the company. SVB Leerink increased their price objective on Pfizer from $39.00 to $43.00 and gave the company a “market perform” rating in a research report on Wednesday, May 5th. JPMorgan Chase & Co. set a $40.00 price objective on Pfizer and gave the company a “neutral” rating in a research report on Monday, May 24th. Mizuho reiterated a “neutral” rating and set a $42.00 price objective on shares of Pfizer in a research report on Wednesday, May 12th. Royal Bank of Canada assumed coverage on Pfizer in a research report on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price objective on the stock. Finally, Barclays increased their price objective on Pfizer from $37.00 to $40.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 5th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $39.73.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: Ex-Dividend

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.